CAS 103475-41-8: tepoxalin

Tepoxalin

Tepoxalin (RWJ 20485), potential asthma and osteoarthritis drug, inhibits COX-1, COX-2, and 5-LOX with low IC50 values.

Applications Non-steroidal anti-inflammatory drug (NSAID) with potent anti-inflammatory and analgesic properties approved for veterinary use. It has inhibitory effect on cyclooxygenase and 5-lipxygenase activity as well as inhibiting the production of cytokines in peripheral cells outside the CNS. References Argentieri, D.C. et al.: J. Pharmacol. Exp. Therap., 271, 1399 (1994); Agnello, K.A. et al.: Am. J. Vet. Res., 66, 966 (2005); Fiebich, B.L. et al.: Neuropharmacol., 38, 1325 (1999);

Tepoxalin is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits prostaglandin synthesis by blocking the cyclooxygenase enzyme. It is used to treat bowel disease and autoimmune diseases, as well as for the prevention of bowel disease in patients with inflammatory bowel disease. Tepoxalin has been shown to inhibit the production of inflammatory mediators such as tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), and nitric oxide in animal models. These effects are due to its inhibition of both COX-1 and COX-2, which are enzymes involved in the synthesis of these mediators. Tepoxalin also shows clinical efficacy in reducing pain and inflammation associated with ophthalmic disorders, such as iritis or corneal ulcers. The toxicological profile includes eye, skin, and respiratory irritation; local tissue damage; immunotoxicity; genotoxicity; carcin